Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors

Nina N. Sanford, Ruoyu Miao, Haotong Wang, Saveli Goldberg, Alex Jacobson, Andrew M. Brunner, Gregory M. Cote, Torunn I. Yock, David H. Ebb, Yi Bin Chen, Kyung Wook Jee, Francis Hornicek, Thomas F. DeLaney, Edwin Choy, Yen Lin Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Long-term survivors of Ewing sarcoma (ES) and osteosarcoma may be at risk for therapy-related acute leukemia or myelodysplastic syndrome (t-AL/MDS). Methods and Materials: We retrospectively reviewed the clinicopathologic characteristics of 1071 patients with osteosarcoma (n = 757) and ES (n = 314) who were treated between 1985 and 2014. Multivariable competing risk analysis was used to analyze predictors of t-AL/MDS, including a radiation dose (≥55.8 Gy vs <55.8 Gy) × disease site (pelvis/spine vs other) interaction term. A supplemental nested case-control study was conducted to assess the association between cumulative chemotherapy dose and t-AL/MDS. Results: The median follow-up for surviving patients was 97 months (range, 0.03-380). Twenty patients developed t-AL/MDS, all of whom received chemotherapy and 15 of whom were treated with radiation therapy. Radiation therapy to ≥55.8 Gy was associated with development of t-AL/MDS (adjusted hazard ratio, 2.89; 95% confidence interval [CI], 1.23-6.80; P =.015), and there was a significant radiation dose × disease site interaction term (adjusted hazard ratio, 6.70; 95% CI, 2.71-16.53; Pinteraction <.001). The 5-year cumulative incidence of t-AL/MDS in patients receiving ≥55.8 Gy radiation therapy to the pelvis or spine was 5.0% (95% CI, 0.9-14.9) for osteosarcoma and 10.7% for ES (95% CI, 3.3-23.2). In our nested case-control study, cumulative doses of ifosfamide and etoposide were associated with development of t-AL/MDS. Conclusions: Patients with osteosarcoma and ES receiving ≥55.8 Gy of radiation therapy to the pelvis or spine appear to be at increased risk for t-AL/MDS. Treatment with high cumulative doses of chemotherapy may further augment this risk.

Original languageEnglish (US)
Pages (from-to)52-61
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume103
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

leukemias
Myelodysplastic Syndromes
Osteosarcoma
Survivors
therapy
Leukemia
Ewing's Sarcoma
predictions
pelvis
spine
confidence
radiation therapy
chemotherapy
dosage
cancer
Radiotherapy
intervals
Pelvis
Confidence Intervals
Radiation Dosage

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors. / Sanford, Nina N.; Miao, Ruoyu; Wang, Haotong; Goldberg, Saveli; Jacobson, Alex; Brunner, Andrew M.; Cote, Gregory M.; Yock, Torunn I.; Ebb, David H.; Chen, Yi Bin; Jee, Kyung Wook; Hornicek, Francis; DeLaney, Thomas F.; Choy, Edwin; Chen, Yen Lin.

In: International Journal of Radiation Oncology Biology Physics, Vol. 103, No. 1, 01.01.2019, p. 52-61.

Research output: Contribution to journalArticle

Sanford, NN, Miao, R, Wang, H, Goldberg, S, Jacobson, A, Brunner, AM, Cote, GM, Yock, TI, Ebb, DH, Chen, YB, Jee, KW, Hornicek, F, DeLaney, TF, Choy, E & Chen, YL 2019, 'Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors', International Journal of Radiation Oncology Biology Physics, vol. 103, no. 1, pp. 52-61. https://doi.org/10.1016/j.ijrobp.2018.08.037
Sanford, Nina N. ; Miao, Ruoyu ; Wang, Haotong ; Goldberg, Saveli ; Jacobson, Alex ; Brunner, Andrew M. ; Cote, Gregory M. ; Yock, Torunn I. ; Ebb, David H. ; Chen, Yi Bin ; Jee, Kyung Wook ; Hornicek, Francis ; DeLaney, Thomas F. ; Choy, Edwin ; Chen, Yen Lin. / Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors. In: International Journal of Radiation Oncology Biology Physics. 2019 ; Vol. 103, No. 1. pp. 52-61.
@article{734ebe90c9c64bb68ef18cbc1badaec8,
title = "Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors",
abstract = "Purpose: Long-term survivors of Ewing sarcoma (ES) and osteosarcoma may be at risk for therapy-related acute leukemia or myelodysplastic syndrome (t-AL/MDS). Methods and Materials: We retrospectively reviewed the clinicopathologic characteristics of 1071 patients with osteosarcoma (n = 757) and ES (n = 314) who were treated between 1985 and 2014. Multivariable competing risk analysis was used to analyze predictors of t-AL/MDS, including a radiation dose (≥55.8 Gy vs <55.8 Gy) × disease site (pelvis/spine vs other) interaction term. A supplemental nested case-control study was conducted to assess the association between cumulative chemotherapy dose and t-AL/MDS. Results: The median follow-up for surviving patients was 97 months (range, 0.03-380). Twenty patients developed t-AL/MDS, all of whom received chemotherapy and 15 of whom were treated with radiation therapy. Radiation therapy to ≥55.8 Gy was associated with development of t-AL/MDS (adjusted hazard ratio, 2.89; 95{\%} confidence interval [CI], 1.23-6.80; P =.015), and there was a significant radiation dose × disease site interaction term (adjusted hazard ratio, 6.70; 95{\%} CI, 2.71-16.53; Pinteraction <.001). The 5-year cumulative incidence of t-AL/MDS in patients receiving ≥55.8 Gy radiation therapy to the pelvis or spine was 5.0{\%} (95{\%} CI, 0.9-14.9) for osteosarcoma and 10.7{\%} for ES (95{\%} CI, 3.3-23.2). In our nested case-control study, cumulative doses of ifosfamide and etoposide were associated with development of t-AL/MDS. Conclusions: Patients with osteosarcoma and ES receiving ≥55.8 Gy of radiation therapy to the pelvis or spine appear to be at increased risk for t-AL/MDS. Treatment with high cumulative doses of chemotherapy may further augment this risk.",
author = "Sanford, {Nina N.} and Ruoyu Miao and Haotong Wang and Saveli Goldberg and Alex Jacobson and Brunner, {Andrew M.} and Cote, {Gregory M.} and Yock, {Torunn I.} and Ebb, {David H.} and Chen, {Yi Bin} and Jee, {Kyung Wook} and Francis Hornicek and DeLaney, {Thomas F.} and Edwin Choy and Chen, {Yen Lin}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2018.08.037",
language = "English (US)",
volume = "103",
pages = "52--61",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors

AU - Sanford, Nina N.

AU - Miao, Ruoyu

AU - Wang, Haotong

AU - Goldberg, Saveli

AU - Jacobson, Alex

AU - Brunner, Andrew M.

AU - Cote, Gregory M.

AU - Yock, Torunn I.

AU - Ebb, David H.

AU - Chen, Yi Bin

AU - Jee, Kyung Wook

AU - Hornicek, Francis

AU - DeLaney, Thomas F.

AU - Choy, Edwin

AU - Chen, Yen Lin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Long-term survivors of Ewing sarcoma (ES) and osteosarcoma may be at risk for therapy-related acute leukemia or myelodysplastic syndrome (t-AL/MDS). Methods and Materials: We retrospectively reviewed the clinicopathologic characteristics of 1071 patients with osteosarcoma (n = 757) and ES (n = 314) who were treated between 1985 and 2014. Multivariable competing risk analysis was used to analyze predictors of t-AL/MDS, including a radiation dose (≥55.8 Gy vs <55.8 Gy) × disease site (pelvis/spine vs other) interaction term. A supplemental nested case-control study was conducted to assess the association between cumulative chemotherapy dose and t-AL/MDS. Results: The median follow-up for surviving patients was 97 months (range, 0.03-380). Twenty patients developed t-AL/MDS, all of whom received chemotherapy and 15 of whom were treated with radiation therapy. Radiation therapy to ≥55.8 Gy was associated with development of t-AL/MDS (adjusted hazard ratio, 2.89; 95% confidence interval [CI], 1.23-6.80; P =.015), and there was a significant radiation dose × disease site interaction term (adjusted hazard ratio, 6.70; 95% CI, 2.71-16.53; Pinteraction <.001). The 5-year cumulative incidence of t-AL/MDS in patients receiving ≥55.8 Gy radiation therapy to the pelvis or spine was 5.0% (95% CI, 0.9-14.9) for osteosarcoma and 10.7% for ES (95% CI, 3.3-23.2). In our nested case-control study, cumulative doses of ifosfamide and etoposide were associated with development of t-AL/MDS. Conclusions: Patients with osteosarcoma and ES receiving ≥55.8 Gy of radiation therapy to the pelvis or spine appear to be at increased risk for t-AL/MDS. Treatment with high cumulative doses of chemotherapy may further augment this risk.

AB - Purpose: Long-term survivors of Ewing sarcoma (ES) and osteosarcoma may be at risk for therapy-related acute leukemia or myelodysplastic syndrome (t-AL/MDS). Methods and Materials: We retrospectively reviewed the clinicopathologic characteristics of 1071 patients with osteosarcoma (n = 757) and ES (n = 314) who were treated between 1985 and 2014. Multivariable competing risk analysis was used to analyze predictors of t-AL/MDS, including a radiation dose (≥55.8 Gy vs <55.8 Gy) × disease site (pelvis/spine vs other) interaction term. A supplemental nested case-control study was conducted to assess the association between cumulative chemotherapy dose and t-AL/MDS. Results: The median follow-up for surviving patients was 97 months (range, 0.03-380). Twenty patients developed t-AL/MDS, all of whom received chemotherapy and 15 of whom were treated with radiation therapy. Radiation therapy to ≥55.8 Gy was associated with development of t-AL/MDS (adjusted hazard ratio, 2.89; 95% confidence interval [CI], 1.23-6.80; P =.015), and there was a significant radiation dose × disease site interaction term (adjusted hazard ratio, 6.70; 95% CI, 2.71-16.53; Pinteraction <.001). The 5-year cumulative incidence of t-AL/MDS in patients receiving ≥55.8 Gy radiation therapy to the pelvis or spine was 5.0% (95% CI, 0.9-14.9) for osteosarcoma and 10.7% for ES (95% CI, 3.3-23.2). In our nested case-control study, cumulative doses of ifosfamide and etoposide were associated with development of t-AL/MDS. Conclusions: Patients with osteosarcoma and ES receiving ≥55.8 Gy of radiation therapy to the pelvis or spine appear to be at increased risk for t-AL/MDS. Treatment with high cumulative doses of chemotherapy may further augment this risk.

UR - http://www.scopus.com/inward/record.url?scp=85057873066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057873066&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2018.08.037

DO - 10.1016/j.ijrobp.2018.08.037

M3 - Article

C2 - 30165126

AN - SCOPUS:85057873066

VL - 103

SP - 52

EP - 61

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -